Biovista and Hewlett Packard Enterprise to collaborate on next generation AI and Big Data Analytics to advance real-world personalized medicine at community hospital settings. CHARLOTTESVILLE, Va., Aug. 10, 2017 /PRNewswire/ — Biovista announced today that it is collaborating with HPE to advance Biovista’s Project Prodigy Big Data AI healthcare platform applied in the personalized medicine … Read More
Author: Vassilis Virvilis
Sarah Bush Lincoln to Use Biovista’s Project Prodigy Artificial Intelligence Engine to Identify and Validate New Therapeutic Options for Further Research
Charlottesville, VA (PRWEB) January 19, 2017 Sarah Bush Lincoln (SBL), a hospital and health care organization that is home to more than 300,000 provider office visits per year, and Biovista announced today that they will be working together to validate novel therapeutic options generated in the real-world practice of a hospital and health center, using … Read More
Biovista announces strong preclinical results for two drugs targeting Niemann-Pick Disease Type A
CHARLOTTESVILLE, Va. – Jan. 12, 2017 – Biovista Inc. today announced that two drugs targeting Niemann-Pick Disease Type A (NPA), have shown strong positive results in the Acid Sphingomyelinase ASM knock-out (ASMKO) mouse model. Both repositioning candidates (BVA-901A and BVA-901B) tested by the laboratory of Dr. M.D. Ledesma at the Madrid Center for Molecular Biology … Read More
New Biovista Inc. Publication: EMR Data Confirm Big Data Analytics Prediction That Hypothyroidism is a Risk Factor for New-onset Diabetes Mellitus
CHARLOTTESVILLE, Virginia, June 23, 2015 /PRNewswire/ — Biovista Inc. today announced the publication of data from research it carried out in collaboration with the FDA and Israeli HMO Clalit, focusing on the prediction of risk factors related to targeted diseases. The research, published in the American Diabetes Association journal Diabetes Care, identifies hypothyroidism as a … Read More
What Role for Systematic Drug Repositioning?
In an ideal world we shouldn’t need drug repositioning. In an ideal world we would know exactly how drugs work, we would have precision medicine and no need to find alternative indications. But we don’t live in an ideal world, not even an almost ideal one. And so for now, there seems to be a role for drug repositioning and even more so for systematic drug repositioning (SDR). But is SDR currently done in the best possible way? What about the art of SDR -how can we integrate SDR within an organization with minimum disruption to existing processes? And could SDR evolve to become a systematic discovery tool?